Receiver operating characteristic curve analyses for the prediction of hepatitis C. by Lu Han (151620)

Subjects:

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

Exploring the correlation between systemic inflammation biomarkers and HCV infection (logarithm base 2). by Lu Han (151620)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Threshold effect analysis of systemic inflammatory biomarkers on hepatitis C using two-piece wise linear regression. by Lu Han (151620)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Exclusion and enrollment summary from NHANES. by Lu Han (151620)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects:

Demographic information and baseline population characteristics. by Lu Han (151620)

Subjects:

Stratified associations between systemic inflammation biomarkers and hepatitis C (OR 95%, <i>P</i> value, LOG base 2). by Lu Han (151620)

Subjects:

General addictive models demonstrate the relationship between systemic inflammatory biomarkers and anti-HCV. by Lu Han (151620)

Subjects:

Comparison of systemic inflammation biomarkers in infected and uninfected populations. by Lu Han (151620)

Subjects:

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

Hypothetical mechanism by which plasma VEGF-A121 concentration is elevated post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

Dam and pup body and brain weights. by Adrienne J. Bradley (20861948)

Subjects:

Reagent list. by Adrienne J. Bradley (20861948)

Subjects: